{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:16:47Z","timestamp":1789823807983,"version":"4.0.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["drugandalcoholdependence.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.drugalcdep.2014.06.005","type":"journal-article","created":{"date-parts":[[2014,6,18]],"date-time":"2014-06-18T00:16:08Z","timestamp":1403050568000},"page":"98-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"special_numbering":"C","title":["Factors contributing to the rise of buprenorphine misuse: 2008\u20132013"],"prefix":"10.1016","volume":"142","author":[{"given":"Theodore J.","family":"Cicero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary L.","family":"Surratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Kurtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2014.06.005_bib0005","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/10826080701434857","article-title":"Buprenorphine misuse in Finland","volume":"42","author":"Aalto","year":"2007","journal-title":"Subst. Use Misuse"},{"key":"10.1016\/j.drugalcdep.2014.06.005_bib0010","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1001\/archinternmed.2010.541","article-title":"Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience","volume":"171","author":"Alford","year":"2011","journal-title":"Arch. Int. Med."},{"key":"10.1016\/j.drugalcdep.2014.06.005_bib0015","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.drugalcdep.2006.09.012","article-title":"Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users","volume":"88","author":"Alho","year":"2007","journal-title":"Drug Alcohol Depend."},{"issue":"Suppl. 1","key":"10.1016\/j.drugalcdep.2014.06.005_bib0020","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1080\/10550490490440780","article-title":"French field experience with buprenorphine","volume":"13","author":"Auriacombe","year":"2004","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.drugalcdep.2014.06.005_bib0025","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/j.1360-0443.2010.03014.x","article-title":"The global diversion of pharmaceutical drugs: opiate treatment and the diversion of pharmaceutical opiates: a clinician's perspective","volume":"105","author":"Bell","year":"2010","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2014.06.005_bib0030","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.drugalcdep.2009.03.020","article-title":"Comparing overdose mortality associated with methadone and buprenorphine treatment","volume":"104","author":"Bell","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2014.06.005_bib0035","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0022-3565(25)20047-7","article-title":"Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans","volume":"247","author":"Bickel","year":"1988","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"Suppl. 4","key":"10.1016\/j.drugalcdep.2014.06.005_bib0040","doi-asserted-by":"crossref","first-page":"S197","DOI":"10.1086\/508184","article-title":"Buprenorphine use: the international experience","volume":"43","author":"Carrieri","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.drugalcdep.2014.06.005_bib0045","article-title":"Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction\u2014A Treatment Improvement Protocol (TIP40)","author":"Center for Substance Abuse Treatment (CSAT)","year":"2004"},{"key":"10.1016\/j.drugalcdep.2014.06.005_bib0050","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S0376-8716(03)00058-9","article-title":"Pharmacokinetics of the combination tablet of buprenorphine and naloxone","volume":"70","author":"Chiang","year":"2003","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2014.06.005_bib0055","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1526-4637.2006.00259.x","article-title":"The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS)","volume":"8","author":"Cicero","year":"2007","journal-title":"Pain Med."},{"key":"10.1016\/j.drugalcdep.2014.06.005_bib0060","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1016\/j.pain.2013.07.025","article-title":"Factors influencing the selection of hydrocodone and oxycodone as primary opioids in substance abusers seeking treatment in the United States","volume":"154","author":"Cicero","year":"2013","journal-title":"Pain"},{"key":"10.1016\/j.drugalcdep.2014.06.005_bib0065","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/pds.1452","article-title":"Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United States","volume":"16","author":"Cicero","year":"2007","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.drugalcdep.2014.06.005_bib0070","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1360-0443.2009.02843.x","article-title":"Abuse liability of intravenous buprenorphine\/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers","volume":"105","author":"Comer","year":"2010","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2014.06.005_bib0075","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.drugalcdep.2009.05.021","article-title":"Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved","volume":"105","author":"Degenhardt","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2014.06.005_bib0080","first-page":"1573","article-title":"Managing opioid addiction with buprenorphine","volume":"73","author":"Donaher","year":"2006","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.drugalcdep.2014.06.005_bib0205","unstructured":"Drug Addiction Treatment Act of, 2000, Public Law 106-310, title XXXV, section 3502(a), 2000. Available at http:\/\/buprenorphine.samsha.gov\/data.html. [accessed 2\/20\/14]"},{"key":"10.1016\/j.drugalcdep.2014.06.005_bib0085","series-title":"National Forensic Laboratory Information System (NFLIS), Special Report: Methadone and Buprenorphine, 2003\u20132008","author":"Drug Enforcement Administration, Office of Diversion Control","year":"2009"},{"key":"10.1016\/j.drugalcdep.2014.06.005_bib0090","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1056\/NEJMcp013579","article-title":"Clinical Practice. Office-based treatment of opioid-dependent patients","volume":"347","author":"Fiellin","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drugalcdep.2014.06.005_bib0095","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/sj.npp.1300251","article-title":"Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers","volume":"28","author":"Greenwald","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.drugalcdep.2014.06.005_bib0100","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1046\/j.1360-0443.2003.00500.x","article-title":"Illicit drug use and injection practices among drug users on methadone and buprenorphine maintenance treatment in France","volume":"98","author":"Guichard","year":"2003","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2014.06.005_bib0105","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1001\/jama.1992.03480200058024","article-title":"A controlled trial of buprenorphine treatment for opioid dependence","volume":"267","author":"Johnson","year":"1992","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2014.06.005_bib0110","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jsat.2014.02.003","article-title":"Abuse and diversion of buprenorphine sublingual tablets and film","volume":"47","author":"Lavonas","year":"2014","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2014.06.005_bib0115","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1046\/j.1360-0443.1998.9344753.x","article-title":"Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial","volume":"1998","author":"Ling","year":"1998","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2014.06.005_bib0120","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1517\/14656560903213405","article-title":"The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence","volume":"10","author":"Mammen","year":"2009","journal-title":"Expert Opin. Pharmacother."},{"issue":"Suppl. 2","key":"10.1016\/j.drugalcdep.2014.06.005_bib0125","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S0376-8716(03)00057-7","article-title":"Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment?","volume":"70","author":"Mendelson","year":"2003","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2014.06.005_bib0130","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.drugpo.2008.07.004","article-title":"Why don\u2019t out-of-treatment individuals enter methadone treatment programmes?","volume":"21","author":"Peterson","year":"2010","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.drugalcdep.2014.06.005_bib0135","series-title":"Highlights of Prescribing Information","author":"Reckitt Benckiser Pharmaceuticals Inc.","year":"2014"},{"issue":"Suppl. 1","key":"10.1016\/j.drugalcdep.2014.06.005_bib0140","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.drugalcdep.2006.01.006","article-title":"History and current perspectives on the use of drug formulations to decrease the abuse of prescription drugs","volume":"83","author":"Schuster","year":"2006","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2014.06.005_bib0145","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1080\/10550490802268835","article-title":"Attitudes toward buprenorphine and methadone among opioid-dependent individuals","volume":"17","author":"Schwartz","year":"2008","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.drugalcdep.2014.06.005_bib0150","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s002130000637","article-title":"Effects of buprenorphine\/naloxone in opioid-dependent humans","volume":"154","author":"Stoller","year":"2001","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.drugalcdep.2014.06.005_bib0155","series-title":"National Estimates of Drug-Related Emergency Department Visits 2004\u20132009","author":"Substance Abuse and Mental Health Services Administration","year":"2011"},{"key":"10.1016\/j.drugalcdep.2014.06.005_bib0160","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA):2014 Center for Substance Abuse Treatment (CSAT), undated. Buprenorphine. Available from: http:\/\/buprenorphine.samhsa.gov.[accessed 2\/20\/14]."},{"key":"10.1016\/j.drugalcdep.2014.06.005_bib0165","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jsat.2007.08.004","article-title":"Buprenorphine\/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors","volume":"35","author":"Sullivan","year":"2008","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2014.06.005_bib0170","series-title":"Misuse of Buprenorphine-Related Products, SENTRY Drug Alert Watch, February 22, 2011","author":"United States Department of Justice","year":"2011"},{"key":"10.1016\/j.drugalcdep.2014.06.005_bib0175","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0376-8716(02)00312-5","article-title":"Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France","volume":"69","author":"Vidal-Trecan","year":"2003","journal-title":"Drug Alcohol Depend."},{"issue":"Suppl. 2","key":"10.1016\/j.drugalcdep.2014.06.005_bib0180","first-page":"S13L S27","article-title":"The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic","volume":"70","author":"Walsh","year":"2003","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2014.06.005_bib0185","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/clpt.1994.71","article-title":"Clinical pharmacology of buprenorphine: ceiling effects at high doses","volume":"55","author":"Walsh","year":"1994","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.drugalcdep.2014.06.005_bib0190","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2174\/1874473711104010028","article-title":"Buprenorphine and buprenorphine\/naloxone diversion, misuse, and illicit use: an international review","volume":"4","author":"Yokell","year":"2011","journal-title":"Curr. Drug Abuse Rev."},{"key":"10.1016\/j.drugalcdep.2014.06.005_bib0195","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3390\/ijerph6020787","article-title":"Attitudes toward methadone among out-of-treatment minority injection drug users: implications for health disparities","volume":"6","author":"Zaller","year":"2009","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.drugalcdep.2014.06.005_bib0200","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/10550887.2011.642757","article-title":"The emerging buprenorphine epidemic in the United States","volume":"31","author":"Wish","year":"2012","journal-title":"J. Addict. Dis."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871614009132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871614009132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T10:58:20Z","timestamp":1746269900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871614009132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":41,"alternative-id":["S0376871614009132"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2014.06.005","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors contributing to the rise of buprenorphine misuse: 2008\u20132013","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2014.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}